Shiv ShankerPunna

This study helps to determine the efficacy of tacrolimus (generic form) in renal transplant patients in India. To assess the efficacy of tacrolimus in renal transplant recipients by using graft survival rate (primary objective) and patient survival rate (secondary objective). This is a retrospective study involving collection of data from medical records of patients who underwent renal transplantation in between JUNE 2010-JUNE 2013 at a tertiary care hospital) in India. Study population involves 65 patients between age group of 10-60 years, Male and Female gender, patients receiving tacrolimus (generic form) in their immunosuppressive regimen. Exclusion criteria involved patients with hyperacute graft dysfunction, patients who did not receive tacrolimus as a part of immuno suppressive regimen. Tacrolimus was given in combination with mycophenolatemofetil, corticosteroids. Tacrolimus was given at a dose of 0.15 mg/kg and titrated based on the graft function, trough levels of tacrolimus and other parameters. Of 65 patients,59 were men and 6 were women.86% of patients received graft from living donor, where as 14 % of patients received from cadaveric donor. Graft survival rates for the 1st, 2nd, 3rd years of transplantation were found to be 93.84%,89.23%,87.68 %.Patient survival rate was 98.46% during the 1st year, and it remained same for the succeeding years with no loss of patient lives. The main limitations of this study are inadequate sample size and retrospective nature of study. Through this study, it was concluded that tacrolimus(generic form) demonstrated efficacy in majority of renal transplant patients in preventing graft rejection and maintained favorable function for a period of 3 years.